市場概況

The market for therapeutics to treat Crohn’s disease is projected to grow at a CAGR of 7.6% から 2023 に 2029, reaching USD 23.63 10億まで 2029, compared to USD 13.86 億で 2022. Crohn’s disease, an inflammatory bowel disease, causes digestive tract inflammation and symptoms like abdominal pain, severe diarrhea, and weight loss. The market is dominated by Crohn’s disease in the inflammatory bowel disease treatment sector. The US has the highest prevalence of Crohn’s disease, followed by the UK and China. The rising prevalence drives the market’s growth. Over 100 assets are in development for Crohn’s disease, with most in Phase II. Anti-interleukin and integrin antibodies are the primary drugs in the pipeline. The US leads in global clinical trials. Biologics like anti-TNFs are widely used, but new therapies with better mechanisms of action and convenience are needed. Microbiome-based therapeutics show promise. Major companies invest in research, 買収, and collaborations. Multiple therapies have been launched, including Humira, Remicade, and Stelara. Five major companies have approved drugs for Crohn’s disease.

レポートは市場規模と成長をカバーしています, セグメンテーション, 競争環境, trends and strategies for global Crohn’s disease therapeutics market. 利害関係者が現在の市場機会を活用できるように、市場の定量的な分析を提供します。. このレポートはまた、市場動向と主要な競合他社のアプローチに基づいて、機会と戦略の上位セグメントを特定します。.

市場セグメンテーション

The market is segmented based on various factors, including drug class, gender type, age group, disease type, そして地理.
Drug class: 5-aminosalicylates, TNF-alpha inhibitors, その他
Gender: 男性, 女性
Age group: 49 yrs. & 下に, 50 yrs. & その上
Disease type: large intestinal type, small intestinal type, small/large intestinal type

Segmentation by Geography
North America – US
Europe – Germany, フランス, イギリス, イタリア, スペイン
APAC – 中国, 日本

TNF-Alpha inhibitors hold a significant share in the global Crohn’s disease therapeutics market, but other drug classes are expected to grow rapidly. Skyrizi’s approval will drive the market. New mechanisms of action are being researched to address non-response issues. Launch of new drugs for moderate-to-severe patients will contribute to market growth. Anti-integrin and interleukin inhibitors gain popularity. Women have a substantial presence. The small intestinal type grows fastest. Individuals aged 49 and below dominate. The US dominates, but the UK will grow rapidly. Biosimilars impact China and Japan.

競争環境

The Crohn’s disease treatment market is dominated by generic medication providers and selective pharmaceutical and biotechnology companies. Key companies in this market include AbbVie Inc., AstraZeneca plc, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celltrion, 株式会社, ジョンソン & ジョンソン (J&J), Redhill Biopharma Ltd., Takeda Pharmaceutical Company Limited, UCB SA, とりわけ.

最近の業界の発展

AbbVie achieved a significant milestone in June 2022 with the FDA approval of SKYRIZI (risankizumab-rzaa), the first and only IL-23 inhibitor for moderately to severely active Crohn’s disease (CD). The approval was based on positive results from the ADVANCE and MOTIVATE studies, which evaluated risankizumab’s efficacy and safety in comparison to placebo.

In May 2022, AbbVie announced positive topline results from the Phase 3 U-ENDURE maintenance study, showing that upadacitinib demonstrated superior efficacy compared to placebo in achieving endoscopic response and clinical remission in patients with moderate to severe Crohn’s disease.

Ossium Health received FDA acceptance of its IND application for OSSM-001 in March 2022. OSSM-001, a mesenchymal stem cell product, aims to treat refractory perianal fistulas in Crohn’s disease patients. Ossium is now preparing for a Phase 1 clinical trial to evaluate the safety and efficacy of OSSM-001, expected to begin by the end of 2022.

報告書の範囲

To analyze and forecast the market size of the global Crohn’s disease therapeutics market.
To classify and forecast the global Crohn’s disease therapeutics market based on drug class, gender, age group, disease type, 地理.
To identify drivers and challenges for the global Crohn’s disease therapeutics market.
合併などの競争展開を検討するため & 買収, 協定, コラボレーションとパートナーシップ, 等, in the global Crohn’s disease therapeutics market.
To identify and analyze the profile of leading players operating in the global Crohn’s disease therapeutics market.

このレポートを選択する理由

Gain a reliable outlook of the global Crohn’s disease therapeutics market forecasts from 2023 に 2029 シナリオ全体にわたって.
投資対象となる成長セグメントを特定する.
会社概要と市場データを通じて競合他社に先んじる.
Excel 形式でのシナリオ全体の分析を容易にするための市場予測.
3ヶ月間の戦略コンサルティングとリサーチサポート.
シングルユーザーライセンスに提供される印刷認証.